Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.

Literature DB >> 30811294

MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.

D Ross Camidge¹, Kurtis D Davies¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2019 PMID： 30811294 PMCID： PMC6455716 DOI： 10.1200/JCO.19.00033

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

9 in total

1. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Authors: Gillianne G Y Lai; Tse Hui Lim; John Lim; Perry J R Liew; Xue Lin Kwang; Rahul Nahar; Zaw Win Aung; Angela Takano; Yin Yeng Lee; Dawn P X Lau; Gek San Tan; Sze Huey Tan; Wan Ling Tan; Mei-Kim Ang; Chee Keong Toh; Bien Soo Tan; Anantham Devanand; Chow Wei Too; Apoorva Gogna; Boon Hean Ong; Tina P T Koh; Ravindran Kanesvaran; Quan Sing Ng; Amit Jain; Tanujaa Rajasekaran; Ju Yuan; Tony Kiat Hon Lim; Alvin S T Lim; Axel M Hillmer; Wan Teck Lim; N Gopalakrishna Iyer; Wai Leong Tam; Weiwei Zhai; Eng-Huat Tan; Daniel S W Tan
Journal: J Clin Oncol Date: 2019-01-24 Impact factor: 44.544

Review 2. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors: Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal: J Thorac Oncol Date: 2016-10-26 Impact factor: 15.609

3. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Authors: Yi-Long Wu; Li Zhang; Dong-Wan Kim; Xiaoqing Liu; Dae Ho Lee; James Chih-Hsin Yang; Myung-Ju Ahn; Johan F Vansteenkiste; Wu-Chou Su; Enriqueta Felip; Vincent Chia; Sabine Glaser; Philippe Pultar; Sylvia Zhao; Bin Peng; Mikhail Akimov; Daniel S W Tan
Journal: J Clin Oncol Date: 2018-08-29 Impact factor: 44.544

4. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors: Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743

5. MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Authors: Matthew A Smith; Thomas Licata; Aliya Lakhani; Marileila Varella Garcia; Hans-Ulrich Schildhaus; Vincent Vuaroqueaux; Balazs Halmos; Alain C Borczuk; Y Ann Chen; Benjamin C Creelan; Theresa A Boyle; Eric B Haura
Journal: Clin Cancer Res Date: 2017-08-29 Impact factor: 12.531

6. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors: Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal: Clin Cancer Res Date: 2013-03-07 Impact factor: 12.531

7. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.

Authors: Sinéad A Noonan; Lynne Berry; Xian Lu; Dexiang Gao; Anna E Barón; Patrick Chesnut; Jamie Sheren; Dara L Aisner; Dan Merrick; Robert C Doebele; Marileila Varella-Garcia; D Ross Camidge
Journal: J Thorac Oncol Date: 2016-06-01 Impact factor: 15.609

8. Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.

Authors: Joel P Womack; Marileila Varella-Garcia; D Ross Camidge
Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609

9. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Authors: Zofia Piotrowska; Hideko Isozaki; Jochen K Lennerz; Justin F Gainor; Inga T Lennes; Viola W Zhu; Nicolas Marcoux; Mandeep K Banwait; Subba R Digumarthy; Wenjia Su; Satoshi Yoda; Amanda K Riley; Varuna Nangia; Jessica J Lin; Rebecca J Nagy; Richard B Lanman; Dora Dias-Santagata; Mari Mino-Kenudson; A John Iafrate; Rebecca S Heist; Alice T Shaw; Erica K Evans; Corinne Clifford; Sai-Hong I Ou; Beni Wolf; Aaron N Hata; Lecia V Sequist
Journal: Cancer Discov Date: 2018-09-26 Impact factor: 39.397